Date:10/25/2011

of SB-728-T. Data from its Phase 1 clinical programs to develop SB-728-T, a novel ZFP nuclease (ZFN)-based therapeutic approach for the treatment of HIV/AIDS, were discussed in two presentations at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  Based on these data, the Company expects to initiate two new clinical trials designed to maximize the engraftment of CD4+ T-cells that are have undergone biallelic ZFN-mediated modification of the CCR5 gene.

Appointment of Dr. Geoffrey Nichol, M.B., Ch.B., as Executive Vice President, Research and Development. In this newly created position, Dr. Nichol oversees all of the Company's research and clinical development activities and operations.

Publication of Studies Demonstrating the Use of ZFN Technology for the Correction of the Alpha1-Antitrypsin Gene in induced Pluripotent Stem Cells (iPSCs) and the Efficient Generation of Transgenic Pigs. Sangamo scientists published a preclinical study in Nature demonstrating highly specific, functional correction of the alpha1-antitrypsin (A1AT) gene defect in patient-derived iPSCs using ZFNs.  The work highlights the precision and broad applicability of ZFN-based genome-editing for the development of ZFP Therapeutics® for the treatment of monogenic diseases. In a second publication in the Proceedings of the National Academy of Sciences (PNAS), scientists demonstrated the use of ZFNs to produce genetically modified pigs.  This work represents a significant advancement in the development of improved, less immunogenic, animal tissue as a source for transplant into humans.

Conference CallSangamo will host a conference call today, October 25, 2011 at 5:00 p.m. ET, which will be open to the public.  The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" '/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
3. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
4. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
5. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
6. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
8. Sangamo Announces Pricing of Public Offering of Common Stock
9. Sangamo Announces Public Offering of Common Stock
10. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
11. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference